Vol. 3 No. 4 (2023)
Reimbursement Reviews

Lemborexant (Dayvigo)

decorative image

Published April 19, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses lemborexant (Dayvigo), 5 mg per tablet and 10 mg per tablet, oral.
  • Indication: For the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.